UBS Group’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-594,919
| Closed | -$40.3M | – | 8751 |
|
|
2019
Q3 | $40.3M | Buy |
594,919
+565,509
| +1,923% | +$38.8M | 0.02% | 805 |
|
|
2019
Q2 | $1.71M | Sell |
29,410
-22,075
| -43% | -$1.31M | ﹤0.01% | 3284 |
|
|
2019
Q1 | $3.61M | Sell |
51,485
-38,233
| -43% | -$2.83M | ﹤0.01% | 2476 |
|
|
2018
Q4 | $5.78M | Buy |
89,718
+62,572
| +231% | +$4.39M | ﹤0.01% | 2027 |
|
|
2018
Q3 | $1.91M | Sell |
27,146
-1,468
| -5% | -$85.9K | ﹤0.01% | 3261 |
|
|
2018
Q2 | $1.44M | Sell |
28,614
-16,595
| -37% | -$658K | ﹤0.01% | 3458 |
|
|
2018
Q1 | $1.42M | Sell |
45,209
-16,343
| -27% | -$542K | ﹤0.01% | 3417 |
|
|
2017
Q4 | $2.1M | Buy |
61,552
+1,862
| +3% | +$59.4K | ﹤0.01% | 3150 |
|
|
2017
Q3 | $1.92M | Buy |
59,690
+33,391
| +127% | +$1.05M | ﹤0.01% | 3163 |
|
|
2017
Q2 | $856K | Buy |
26,299
+7,290
| +38% | +$231K | ﹤0.01% | 3747 |
|
|
2017
Q1 | $599K | Sell |
19,009
-2,407
| -11% | -$71.2K | ﹤0.01% | 3918 |
|
|
2016
Q4 | $629K | Buy |
21,416
+11,608
| +118% | +$354K | ﹤0.01% | 3936 |
|
|
2016
Q3 | $283K | Sell |
9,808
-1,480
| -13% | -$41.2K | ﹤0.01% | 4297 |
|
|
2016
Q2 | $293K | Sell |
11,288
-5,462
| -33% | -$145K | ﹤0.01% | 4280 |
|
|
2016
Q1 | $415K | Sell |
16,750
-14,250
| -46% | -$391K | ﹤0.01% | 3917 |
|
|
2015
Q4 | $1.09M | Buy |
31,000
+22,271
| +255% | +$596K | ﹤0.01% | 3340 |
|
|
2015
Q3 | $185K | Buy |
8,729
+2,753
| +46% | +$70.9K | ﹤0.01% | 4703 |
|
|
2015
Q2 | $166K | Buy |
5,976
+2,864
| +92% | +$80.8K | ﹤0.01% | 5029 |
|
|
2015
Q1 | $95K | Buy |
3,112
+962
| +45% | +$30.6K | ﹤0.01% | 5455 |
|
|
2014
Q4 | $69K | Buy |
+2,150
| New | +$70K | ﹤0.01% | 6089 |
|
UBS Group's GHDX Position: Q4 2019 in Review
UBS Group sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 594,919 shares — an estimated $40.3M sold.
UBS Group first reported a position in GHDX in Q4 2014 and held it in 20 quarters. The position peaked at $40.3M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- UBS Group reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- UBS Group sold 594,919 Genomic Health, Inc. shares in Q4 2019, an estimated $40.3M.
- UBS Group first reported a position in Genomic Health, Inc. in Q4 2014 and held it in 20 quarters.
- UBS Group's Genomic Health, Inc. position peaked at $40.3M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.